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Introduction 
Cognitive enhancement can benefit the individual and society, but also has associated 
risks and ethical concerns. Cognitive-enhancing drugs are used in the treatment of 
neuropsychiatric disorders. Non-pharmacological strategies are also emerging, which 
have the potential to improve motivational deficits associated with neuropsychiatric 
symptoms and should be prioritized for development. The increasing lifestyle use of 
‘smart’ and other drugs indicates the desire for healthy people to improve themselves. 
Safety and ethical implications are discussed.  
 
Restoring cognitive function  
Cognitive dysfunction is characteristic of neuropsychiatric disorders, creating a clear need for 
effective strategies to restore, for example, attentional biases, aberrant learning, dysfunctional 
reward systems and dysregulation in top-down cognitive control by the prefrontal cortex1. 
Disturbances in emotional and motivational processes, such as apathy and withdrawal, affect 
outcome and remain complex barriers to treatment entry and engagement. These challenges 
impact on the functionality and wellbeing of patients and their carers. Each year, the direct 
and indirect costs of neuropsychiatric disorders are widespread, with implications for the 
government (increasing demands on healthcare/social services), the economy (lost 
productivity/earnings) and the quality of patient life (difficulty to live/work independently).   
 
While cholinesterase inhibitors, such as donepezil, and stimulants, such as methylphenidate, 
are used in the treatment of cognitive symptoms in Alzheimer’s disease and attention deficit 
hyperactivity disorder (ADHD) respectively, there are as yet no drugs approved by the 
FDA/EMA/MHRA for the treatment of cognitive dysfunction in depression, schizophrenia or 
mild cognitive impairment (MCI). Improving cognitive dysfunction could help alleviate some 
of the economic and societal costs of disease burden. Cognitive-enhancing drugs would also 
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be useful for disorders in which cognitive impairments persist even after successful treatment 
of the more acute symptoms (e.g. low mood in depression, psychotic symptoms). In addition 
to drugs, non-pharmacological cognitive-enhancers can be used to treat cognitive dysfunction 
in neuropsychiatric and neurodegenerative disorders. These include brain stimulation devices 
and cognitive training packages that are designed to improve neural circuitry leading to 
neuroplasticity. The clearest benefits found thus far are in depression (improvement in 
treatment-resistant symptoms following transcranial magnetic stimulation) and schizophrenia 
(cognitive remediation of memory deficits)1,2.  
 
Computer games are highly rewarding and, in our opinion, an exciting option for delivering 
targeted cognitive training. We previously demonstrated that gamified cognitive training 
(www.peak.net/advanced-training; Figure 1) can improve episodic memory and functional 
outcome in patients with schizophrenia1. Importantly, high levels of enjoyment and desire to 
continue were maintained throughout all hours of gameplay, which we believe represents a 
motivational improvement over traditional (usually boring) cognitive training paradigms.  
 
Cognitive training is also effective for improving cognition and functional abilities in 
individuals with MCI3. Pharmacological interventions that slow progression from MCI to 
Alzheimer’s disease are currently under development. As cholinesterase inhibitors are most 
likely to be effective in the treatment of attentional dysfunction, alternative strategies for 
treating memory problems are needed. Despite the potential benefits of cognitive training, the 
cost and inconvenience of delivery (e.g. specialized equipment, participant travel, 
supervision), in addition to motivational deficits associated with apathetic or depressive 
symptoms often characteristic of older populations with memory difficulties, leads to 
considerable dropout. We propose that gamified cognitive training could circumvent dropout 
rates by maximizing engagement in patients with deficits in motivation, primarily in MCI but 
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also ADHD, and further extend to other populations with a high prevalence of 
neuropsychiatric symptoms, such as traumatic brain injury.  
 
Gamified cognitive training studies with longitudinal designs, active control groups and 
measures of brain and behavioral changes will be critical for evaluating the techniques 
necessary for cognitive and functional improvement, including the optimal dose and duration 
of delivery. We further propose that concurrent gamified cognitive training and 
pharmacological treatments, particularly cognitive-enhancing drugs but also antidepressants 
and antipsychotics, has potential to improve treatment compliance of patients and synergise 
the effects needed for good clinical outcome. Combining findings from neuropsychiatry with 
gaming technology could also reduce some of the stigma associated with mental health 
treatments.  
 
Enhancing cognitive function   
There is increasing use of cognitive enhancers for ‘lifestyle’ rather than medical reasons. This 
is illustrated by modafinil, a wakefulness-promoting agent used in the treatment of sleep-
related disorders. The use of so-called ‘smart drugs’ by the public indicates the desire (or 
pressure) for individuals to better their already healthy cognitive functioning.  
 
Work-related stress is the primary reason for healthy individuals using cognitive-enhancing 
drugs; likewise, students report academic competition and amplified feelings of concentration 
and wakefulness as their top motivators for smart drug use2. Modafinil produces cognitive-
enhancing effects in healthy individuals, mostly in higher executive functions such as 
planning and decision-making. Modafinil also has positive effects on mood. Methylphenidate 
and amphetamine are two stimulants that improve inhibitory control and memory processes in 
healthy individuals. Both drugs are classed as Schedule II controlled substances in the USA, 
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indicating high abuse potential. Regulation of these drugs is therefore essential but difficult to 
control, particularly given the sharing and selling of medications following the rise in 
diagnosis of ADHD in young adults and the ability to purchase medications online. 
 
We recommend physical exercise, education, social interaction, mindfulness and sleep for 
improving cognitive performance and overall wellbeing. Encouragingly, six months of online 
cognitive training showed improved cognition, reasoning and activities of daily living in a 
large number of healthy adults over the age of sixty4. Cognitive training of working memory 
also showed altered functional activation and dopamine receptor density in the brain5. It is our 
opinion that both modafinil and gamified cognitive training can improve task-related 
motivation, but it may be that gamified cognitive training gives a greater sense of 
achievement as improvement in performance is attributed to the self, rather than a drug.   
  
The desire to perform better is not limited to students. The term ‘psychonauts’ describes 
people who experiment with mind-altering chemicals, sometimes to the extent of taking exact 
measurements and keeping records of their experiences. Nootropics is the umbrella term that 
refers to cognitive-enhancing smart drugs, stimulants (prescription medications but also 
caffeine and nicotine), supplements (‘nutracueticals’) and other substances such as racetams. 
Combinations of nootropics called ‘stacks’ are taken to meet the specific needs of the 
consumer based on which cognitive function they feel would most benefit from enhancement. 
Stacks are not FDA-approved for enhancing cognition, but the individual compounds might 
be approved as dietary supplements. However, the potential harm of mixing nootropics, 
including short- and long-term side effects, is unknown. In some cases, the quantities of the 
individual compounds that comprise the final product are not disclosed. Users are therefore 
turning to online forums to discuss their experiences with nootropics, which, although 
This article is protected by copyright. All rights reserved.
Opinions, Clinical Pharmacology and Therapeutics  6
prompting discussion and awareness while maintaining anonymity, could also lead to 
misrepresentation of their effects and harms.  
 
In parallel to the boom in demand for nootropics, ‘microdosing’ psychedelics are an 
increasingly popular phenomenon in which small amounts of psilocybin mushrooms, LSD or 
mescaline are taken to enhance cognitive function, perception and creativity. This adds a new 
dimension to what could be considered ‘illegal cognitive enhancement’. There is thus an 
increase in the type of drugs sought for enhancing cognition. The combination of cognitive 
enhancement with psychoactive effects reflects a change in the use of banned hallucinogenic 
drugs. Characteristics of users, the long-term effects of microdosing and the extent to which 
the legal status of psychedelics impacts on their cost and availability pose novel avenues of 
drug research.  
 
Cognitive enhancement has benefits for jobs that require adaptive learning or attentional 
shifting under high levels of risk or pressure. Cognitive enhancement could also improve the 
performance of shift or sleep-deprived workers, thereby increasing safety, work-related 
efficiency and output. However, a growing number of societal and ethical concerns of smart 
drug use by healthy people have been raised. Societal concerns are mainly focused on the 
safety of purchasing prescription medication online from unregulated manufacturing sources. 
An ethical concern of using smart drugs during exam time, which is regarded by many as 
cheating, has led some Universities to ban their use. Additional concerns include increased 
academic pressure and fears of coercion. The lack of randomized controlled trials in healthy 
people raises a number of health concerns. These include the long-term safety and efficacy of 
cognitive-enhancing drugs, their potential for misuse and their influence on the developing 
brain, all of which have not been investigated to an adequate standard.  
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Comment 
Reasons for cognitive enhancement are diverse: restoration (treatment), enhancement, work-
related motivation and mild euphoria. We thus call for public-private partnership between the 
government and pharmaceutical industry to establish the safety and efficacy of currently well-
used smart drugs, such as modafinil, in healthy people. Cognitive-enhancing drugs are 
beneficial for some patients with neuropsychiatric and neurodegenerative disorders, but we 
also suggest the development of games for cognitive training to simultaneously enhance 
cognition and motivation. We further call for academia and the hugely successful ‘serious’ 
games industry to work together to provide evidence-based non-pharmacological strategies 
for cognitive enhancement, particularly for disorders in which pharmacological interventions 
have failed to treat cognitive dysfunction or do not address the associated motivational 
deficits. We believe that innovation in the field of mental health could improve engagement 
with non-pharmacological strategies of cognitive-enhancement and alter public perception of 
treatment through more widespread use. While pharmacological treatments can be of great 
benefit to patients in terms of cognitive symptoms, other strategies, such as gamified 
cognitive training, may be beneficial if given in combination with cognitive-enhancing drugs 
to achieve the best outcome. The advantages of cognitive enhancement should be considered 
and researched further, but the potential harm for the individual and those around them must 
also be avoided, to ensure that all members of society flourish. 
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Figure 1. Images from ‘Wizard’, an example of gamified cognitive training of episodic memory, which embedded a paired associates learning 
task into a narrative, allowed for the selection of characters, rewarded progress, provided feedback and used visually appealing displays and 
stimulating music to keep users engaged and motivated (with permission from Peak; www.peak.net)  
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